TRDA (Entrada Therapeutics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


TRDA Entrada Therapeutics Inc TRDA
23 GF Score
Price $7.74
GF Value $0.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entrada Therapeutics Notes Receivable?

Entrada Therapeutics TRDA +8.40% 23 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Entrada Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Entrada Therapeutics Notes Receivable Related Terms

Entrada Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Entrada Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entrada Therapeutics Notes Receivable Chart

Entrada Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Entrada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TRDA
23GF Score
Entrada Therapeutics Inc TRDA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entrada Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Entrada Therapeutics (TRDA) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Entrada Therapeutics and its competitors.
Is Entrada Therapeutics' Notes Receivable too high?
Entrada Therapeutics' current Notes Receivable is $0.00 Mil. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Notes Receivable compare to NMRA and MGNX?
Entrada Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Entrada Therapeutics and its competitors. Entrada Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $7.74 — trading 741.3% above its estimated fair value. The current Notes Receivable is $0.00 Mil. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.74 is trading 741.3% above its estimated GF Value™ of $0.92. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $0.92 vs. price of $7.74 (741.3% above fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score

Get the complete analysis for TRDA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.74
Price
$0.92
GF Value